Total investment of 886 billion won… Omnia Bio is expected to become the largest shareholder in 2027
Medipost will enter the CDMO business by acquiring a Canadian drug contract development and manufacturing (CDMO) company.
Medipost announced on the 31st that ‘Medipost CDMO’, established as a wholly owned subsidiary, will invest a total of 90 million Canadian dollars (88.6 billion won) in OmniaBio, a CDMO company based in Canada for cell and gene therapy. .
Medipost CDMO has agreed to acquire a 39.6% stake in Omnia Bio at a cost of C$30 million (KRW 29.5 billion), and will invest in convertible bonds (CB) worth an additional USD 60 million (KRW 59.1 billion) by the end of 2024. did with
From 2027, when convertible bonds are converted to common stock, Medipost CDMO will become the largest shareholder of Omnia Bio.
Omnia Bio is a subsidiary of the Center for Commercialization of Regenerative Medicine (CCRM), a Canadian non-profit organization, and was established for the CDMO business of cell and gene therapy.
It has a consignment production facility for autologous and allogeneic cell therapy products, induced pluripotent stem cells (iPSC), and gene therapy products and a local sales network.
Medipost explained that it has decided to make this investment to enter the cell and gene therapy CDMO business and to advance into the North American market for its stem cell therapy, Cartistem.
A Medipost official said, “Medipost, which has experience in the development of a full cycle of stem cell therapy, and Omnia Bio, which has a history of process development and production capacity for cell and gene therapy products, will be able to maximize synergy in the CDMO business.”
With this investment, Omnia Bio plans to expand research and production facilities with a total area of about 10,000 square meters by 2025.
/yunhap news
ⓒ Hankyung.com, unauthorized reprinting and redistribution prohibited
